BRIEF-GlaxoSmithKline says lung drug meets late-stage study goals
June 20, 2016 at 02:23 AM EDT
* Fulfil study shows superiority of closed triple combination therapy ff/umec/vi versus symbicort turbohaler
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.